Table 2.
Distribution of Clinical, Histopathological, and Genetic Features in Patients With UM with Low PRAME and High PRAME (total 80) from the TCGA Study
| Patients, no. (%)§,|| | |||
|---|---|---|---|
| Feature | Low PRAME n = 40 (50%) | High PRAME n = 40 (50%) | P Value |
| Sex | |||
| Male | 22 (55%) | 23 (57%) | 0.82* |
| Female | 18 (45%) | 17 (42%) | |
| Age at enucleation | 63.68 (39–86) | 59.63 (22–86) | 0.24‡ |
| Largest basal diameter | 15.65 (8–25) | 17.52 (11–25) | 0.03‡ |
| Thickness | 10.67 (6–16) | 10.91 (4–16) | 0.54‡ |
| Mitotic count | |||
| 0–5 | 32 (80%) | 31 (77%) | 0.47† |
| >5–10 | 4 (10%) | 7 (17%) | |
| >11 | 4 (10%) | 2 ( 5%) | |
| Cell type | |||
| Spindle cell | 26 (65%) | 17 (42%) | 0.04* |
| Epithelioid-mixed cell | 14 (35%) | 23 (57%) | |
| Ciliary body involvement | |||
| No | 28 (70%) | 26 (65%) | 0.63* |
| Yes | 12 (30%) | 14 (35%) | |
| Extrascleral extension | |||
| None | 40 (100%) | 34 (85%) | 0.01† |
| < 5 mm | 0 (0%) | 3 (7.5%) | |
| >= 5 mm | 0 (0%) | 3 (7.5%) | |
| TNM stage | |||
| I-IIB | 21 (52%) | 15 (37%) | 0.18* |
| IIIA-IV | 19 (19%) | 25 (44%) | |
| Tumor pigmentation | |||
| Light | 28 (70%) | 11 (28%) | 0.001* |
| Mixed | 7 (18%) | 20 (50%) | |
| Heavy | 5 (13%) | 5 (23%) | |
| Chromosome 3 status | |||
| Disomy | 21 (52%) | 17 (42%) | 0.37* |
| Monosomy | 19 (47%) | 23 (57%) | |
| 8q status | |||
| Normal | 19 (47%) | 2 ( 5%) | <0.001* |
| Gain | 11 (27%) | 16 (40%) | |
| Amplification | 10 (25%) | 22 (55%) | |
| 6p status | |||
| Normal | 21 (52%) | 14 (35%) | 0.11* |
| Gain | 19 (47%) | 26 (65%) | |
| BAP1 mutation | |||
| BAP1 wild type | 25 (63%) | 20 (50%) | 0.26* |
| BAP1 mutated | 15 (38%) | 20 (50%) | |
*
Pearson's χ2 test.
†
Likelihood ratio.
‡
Mann Whitney U test.
§
Percentages are rounded and may not total 100.
||
Percentages were calculated excluding missing data.